Oncology

Latest News

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

June 6th 2025

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell lung cancer (SCLC).

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

FDA approved - wladimir1804 - AdobeStock_408414612.

Darolutamide Gains FDA Approval for Metastatic Castration-Sensitive Prostate Cancer

By Giuliana Grossi

June 3rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

April 9th 2019

Time to Fecal Immunochemical Test Completion for Colorectal Cancer

Cameron B. Haas, MPH Amanda I. Phipps, PhD Anjum Hajat, PhD Jessica Chubak, PhD Karen J. Wernli, PhD

Targeted interventions by patient characteristics to improve fecal immunochemical test completion could reduce disparities in colorectal cancer screening and improve overall compliance with screening recommendations.

April 8th 2019

Alexandra Quinn on the Importance of Sustaining the Role of Community Health Workers in Cancer Care

Alexandra Quinn, chief executive officer, Health Leads, discusses the growing role of community health workers in cancer care and why it's important to make the work they do more sustainable.

April 8th 2019

Erich Mounce Discusses How Technology Needs to Evolve to Help Oncologists Deliver Care

Oncology needs to learn to use technology not just for keeping medical records, but also for caring for patients, explained Erich Mounce, chief operating officer, OneOncology.

April 7th 2019

NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations

Laura Joszt, MA

Genetic alternations in colorectal cancer (CRC) are linked to different survival and treatment outcomes, according to a study that used next-generation sequencing (NGS) of tumor DNA. The study was published in Journal of Clinical Oncology.

April 5th 2019

Abra Kelson Outlines How Early Intervention Strategies Can Benefit Patient Treatment

Early intervention to identify social needs means issues get caught sooner and patients can avoid or minimize financial toxicity, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.

April 5th 2019

COA Close to Filing OCM 2.0 for Federal Review

Mary Caffrey

The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model.

April 4th 2019

Ben Jones Explains Reimbursement Challenges Facing Community Oncologists

There's still a big disparity in reimbursement between hospitals and community-based practices, but is looking into ways to address this, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.

April 2nd 2019

The PAN Foundation Opens New Waldenstrom Macroglobulinemia Patient Assistance Fund

The Patient Access Network (PAN) Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia, a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.

April 2nd 2019

MyPath, an App That Uses AI to Guide Patients' Cancer Journeys

Today we’re speaking with Dr Elizabeth Mynatt, the executive director of the Institute for People and Technology and a professor in the College of Computing at the Georgia Institute of Technology. Dr Mynatt and her team developed an app called MyPath that uses artificial intelligence to help guide a patient’s cancer journey.

March 31st 2019

Value-Based Care Is Changing Cancer Treatment Decisions as Drug Costs Continue to Rise

Laura Joszt, MA

As novel therapies drive up the cost of drugs, it is becoming increasingly difficult for community oncologists to keep costs below value-based care program targets, according to a new survey from Integra Connect.

March 30th 2019

Not Just the "Soft Stuff": How Data Deployment, Artificial Intelligence Can Restore Relationships in Oncology Care

Mary Caffrey

The revolution in cancer care isn’t just about the wave of life-saving therapies, or the role of genetics in pinpointing exactly who should get which drug and when. As Ray D. Page, DO, PhD, FACOI, tells it, change also means getting back to the basics, so that the relationship between doctor and patient drives care—not insurance companies or Medicare or rules from the FDA.

March 28th 2019

Heard at ACCC: Addressing Challenges With Cancer Care Delivery With Tom Gallo and Dr Ali McBride

Tom Gallo, the former president of the Association of Community Cancer Centers (ACCC), and Ali McBride, PharmD, the current president of ACCC, discuss how their members feel about the state of cancer delivery, recent trends, addressing burnout, and sustainability of cancer care delivery.

March 27th 2019

Racially Diverse Cell Lines Needed for Precision Medicine to Reach Underrepresented Populations

Laura Joszt, MA

A lack of diversity in cell lines used for laboratory studies means underrepresented populations and minorities might not benefit from precision medicines as quickly as people from European ancestry.

March 27th 2019

Ali McBride, PharmD, MS, BCOP, Becomes ACCC President 2019-2020

Ali McBride, PharmD, MS, BCOP, was named 2019-2020 president of the Association of Community Cancer Centers (ACCC) during its 45th Annual Meeting & Cancer Center Business Summit on March 22, 2019, in Washington, DC. McBride is the clinical coordinator of hematology/oncology at The University of Arizona Cancer Center.

March 27th 2019

Jessa Dunivan: Cohesiveness Is Vital to Maintaining a Successful Care Management Team

Everyone at the practice is vital to the success of value-based care, which is really patient-centered care, said Jessa Dunivan, patient services manager, Northwest Medical Specialties.

March 25th 2019

Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

March 25th 2019

Dr Jarushka Naidoo Discusses Evolution of Biomarker Testing

Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MB BCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

March 25th 2019

Dr Toby Campbell Outlines the Importance of Early End-of-Life Care Discussions

The move to value-based care has increased the use of palliative care, and new research has found that conversations about end-of-life care should be happening earlier, said Toby C. Campbell, MD, MSCI, of the University of Wisconsin Carbone Cancer Center.

March 24th 2019

Abra Kelson Discusses Screening Measures to Highlight High-Risk Patients Who Need Assistance

There are a lot of different ways for identifying patients that might have barriers to care or might be considered as high-risk, says Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.

March 24th 2019

Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved

Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.

March 24th 2019

Podcast: This Week in Managed Care—Cardiovascular Prevention Guidelines and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

March 23rd 2019

Erich Mounce Discusses How Community Oncology Can Address Inequalities in Cancer Care

Erich Mounce, chief operating officer, OneOncology, drew on his experience from West Cancer Center to discuss how community oncology can improve access to care and other inequalities in cancer care.

March 22nd 2019

FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality

Samantha DiGrande

This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.

March 22nd 2019

Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing

CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

March 22nd 2019

This Week in Managed Care: March 22, 2019

This week, the top managed care news included new primary prevention guidelines that could increase the use of some diabetes drugs; the FDA expanded criteria for which patients can take part in clinical trials; a summit on value-based insurance design showed the need for tough conversations with stakeholders.

March 22nd 2019

Dr John Ward on Conversations With Patients After Multigene Testing

Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.

March 22nd 2019

Dr John Sweetenham Discusses the Impact of CMS' Proposal on Access to CAR T-Cell Therapies

CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, of Huntsman Cancer Institute at the University of Utah.

March 22nd 2019

Different Vantage Points, but Similar Goals of High-Value Care, Patient Satisfaction

Laura Joszt, MA

A diverse panel of representatives from different practice models provided insights into what has worked for them and what has not in trying to improve cancer care. The discussion took place in Washington, DC, at the Association of Community Cancer Centers

March 21st 2019

Dr Allen Lichter: Technology Is Present in Oncology, but the Future Is Brighter

While there is currently a presence of technology in healthcare, the future holds much more promise, said Allen Lichter, MD, FASCO, senior partner of TRG Healthcare.

March 20th 2019

Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer

Laura Joszt, MA

Patients with high-risk breast cancer who receive a 21-gene assay genomic test may be able to avoid chemotherapy and ultimately save a significant amount of money.

...

28 29 30 31 32 33 34 35 36

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions